Companies: 10,795·Total market cap: $144.5T
Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

OTLKNASDAQHealthcare● Active
$0.72
$-0.05(-7.04%)
Market Cap$29703369
P/E Ratio
52W High$3.39
52W Low$0.161
Overview

Outlook Therapeutics, Inc. (OTLK) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · OTLK · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.36otlk eps ttm · otlk earnings per shareEarnings history
PE Ratio (TTM)otlk pe ratio ttm · otlk price to earningsPE Ratio deep dive
Revenue (TTM)333141.00otlk revenue ttm · otlk annual revenueFull revenue history
Dividend YieldNo Dividenddoes otlk pay dividends · otlk dividend yieldDividend history
Shares Outstanding34.8Motlk shares outstanding · otlk floatShares outstanding history
Next EarningsAug 13, 2026Est.otlk earnings date · otlk next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$1.4M
202320242025
outlook therapeutics, inc. revenue · otlk revenue 2025
FY 2025Net Income-$62.4M▲ +17.17% YoY
202320242025
outlook therapeutics, inc. net income · otlk profit 2025
FY 2025EPS$-1.79▲ +55.91% YoY
202320242025
otlk eps · outlook therapeutics, inc. earnings per share 2025
TTM:Revenue: $333141.00Net Income: -$61.0MEPS: $-1.36View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy14 analystsis otlk a buy · otlk analyst rating
Strong Buy
0
Buy
7
Hold
7
Sell
0
Strong Sell
0
12-Month Price Target
$1.00Low
$0.72Current
$1.00Avg Target38.50% upside
$1.00High
otlk price target · otlk 12 month forecast

Total: 14 · Buy rate: 50.0%

The OTLK analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $1.00, representing +38.50% upside from the current price of $0.72.

Stock Performance

Full History
1D-7.04%
1W-9.86%
1M+226.25%
3M+74.40%
YTD-54.30%
1Y-62.00%
5Y-98.64%

About Outlook Therapeutics, Inc.

CEORobert Charles Jahr
IPO DateJun 14, 2016
Employees23
CountryUS

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye con…

what is outlook therapeutics, inc. · otlk stock overview · outlook therapeutics, inc. company profile · who is outlook therapeutics, inc. ceo · otlk NASDAQ · outlook therapeutics, inc. headquarters · outlook therapeutics, inc. business segments

About Stock Overview & Key Data

Outlook Therapeutics, Inc. (OTLK) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 14, 2016. As of the latest trading session, OTLK stock price is $0.72, with a market capitalization of $29.7M. The stock has returned -62.00% over the past 12 months and -54.30% year-to-date.

According to 14 Wall Street analysts, the consensus rating for Outlook Therapeutics, Inc. stock is Buy, with an average 12-month price target of $1.00. In fiscal year 2025, Outlook Therapeutics, Inc. reported revenue of $1.4M and net income of -$62.4M. For detailed data — including Outlook Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Outlook Therapeutics, Inc. (OTLK) stock price is $0.72. The stock is traded on NASDAQ under the ticker symbol OTLK. The 52-week range is $0.16 – $3.39.

OTLK stock priceOTLK quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice